about
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patientsExperience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesBiosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published EvidenceMonoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published EvidenceGlycan analysis of therapeutic glycoproteinsAssessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to AdalimumabThe safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.A practical guide about biosimilar data for health care providers treating inflammatory diseasesComparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS studyEvaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab.Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices.Biosimilars advancements: Moving on to the future.Biosimilar regulation in the EU.Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.Laboratory Scale Production and Purification of a Therapeutic Antibody.Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®.A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima.Biosimilar DMARDs: What Does the Future Hold?A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.Biosimilar biologic drugs: a new frontier in medical care.Molecular and functional analysis of monoclonal antibodies in support of biologics development.Simple NMR methods for evaluating higher order structures of monoclonal antibody therapeutics with quinary structure.Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.
P2860
Q26748630-DF290F5C-BB5E-4925-A228-9DE30D7C5C28Q28066776-FEFE3AA0-9570-4920-8C4E-F4F4F000D8A5Q28073310-F087CEF8-57B1-4C8D-A1A4-910D141F50D4Q28078423-ED2E94D2-700E-4097-BD22-2B858B086BBCQ28082842-52205B42-23AA-4C61-9178-68E48EA96C7BQ28831404-43DA233F-AF5F-43B3-9F95-719BF8EB7FBBQ30397234-9191A845-AEBF-4B6A-9462-FFBB1CEA86ECQ30995889-545CE064-D2CB-413F-86A5-13C12A9821E3Q31085610-36589C77-2335-49B7-BED6-D06203612D61Q33843746-C722E72E-CE89-448A-8C62-0E5BC0BD2AAAQ36303459-85A0BBBF-709D-441A-80E3-3E14ABA6B178Q36485893-E3D03EDF-C8C3-4447-A18D-4AA29D9CC299Q36519316-20563B72-16FC-46B7-8739-6D8F49AC6327Q36759817-41A3B767-0B38-4B3C-91FC-15968313BE63Q37327298-1C937022-E104-4401-A9AD-827A63D7E1C3Q37327321-CAFF923F-F3F2-4D3A-8697-7C2A6DEF7E54Q37604531-A8A1281B-B5CB-41C5-9868-C210C770B4E2Q37616966-AAAB5A3D-7CD4-47CD-8544-9071B0DE596CQ37703405-3C3E366F-AC0C-4650-9607-D8A9EA3A503BQ38291910-3C895B5D-6C85-4620-9EB6-391179FB00C9Q38364577-9CAD39CF-545F-4B81-99B5-DF438DF7E50AQ38570723-BF84B976-C1B6-49B5-9C30-352030B42FA2Q38586029-66BC2EFB-7A93-4E59-96CF-E71AC0E1BB17Q38591241-ED8E586E-CA64-4A0A-A2A5-C5E1960419C4Q38591244-60BFB9D5-D6D2-42D7-B2DF-0F1591769529Q38591272-2DF57A96-3CDC-411F-B44B-A2CD3AA6034DQ38592363-ED92C490-9CCB-4229-ABD8-9B42A04F2965Q38699354-C69AF6BC-7E00-49A4-B9F3-D809E09FF9BAQ38716755-5624A3E8-8312-40B2-A637-49CB2A002612Q38730742-1F97974F-C6D3-4C6C-8BCB-35138EE37CB5Q38736575-C1D6EA6A-0F4C-4593-9754-5F380856A40CQ38760042-A48AB378-145C-4276-8933-3C3DDD92CDA6Q38937842-C0D73460-BD99-4091-A800-87DBC0C61557Q38960108-A08ED5C6-ABB0-4A24-89E6-84A7C612ECDAQ38977625-650CE48E-C368-46E1-A4D8-4682D93C660DQ39200937-1DEF763F-ED1F-4EAC-99C8-E793AAD98A6EQ39451572-4129BE6B-3F3F-45D4-81CD-E3FFD6F2B701Q39654732-C87AEE33-A4C1-4FDF-9A54-734B9962AA55Q39711072-47E7428E-B7B9-4313-9DD8-B2FA8AD1BB1FQ40233716-EE090F78-FAE9-4631-8000-862F5FF69126
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Physicochemical characterization of Remsima.
@ast
Physicochemical characterization of Remsima.
@en
type
label
Physicochemical characterization of Remsima.
@ast
Physicochemical characterization of Remsima.
@en
prefLabel
Physicochemical characterization of Remsima.
@ast
Physicochemical characterization of Remsima.
@en
P2093
P2860
P356
P1476
Physicochemical characterization of Remsima.
@en
P2093
Byoung Oh Kwon
Dong-Il Kim
Jae Won Jeon
Jin Soo Bae
Joon Won Lee
Kyoung Hoon Lee
Shin Jae Chang
Soo Young Lee
Soon Kwan Jung
Yeon Jung Kim
P2860
P304
P356
10.4161/MABS.32221
P577
2014-01-01T00:00:00Z